NeOnc Technologies Advances Brain Cancer Drug NEO212 to Phase II Clinical Trial
AI-Generated Summary
NeOnc Technologies has received FDA authorization to proceed with Phase IIa/IIb clinical trials for NEO212, its investigational oral chemotherapy for central nervous system cancers. This follows a successful Phase I study, with patient enrollment expected to begin before the end of 2025 across leading U.S. cancer centers.
In a nutshell
This development marks a significant step in the ongoing effort to find more effective treatments for aggressive brain cancers, as NEO212 aims to improve upon the current standard of care. If successful, it could offer a new and potentially transformative therapeutic option for patients battling these challenging malignancies.
Source: The Manila Times
